Holzer Holzer & Fistel, LLC is investigating whether the directors of Santarus, Inc. (“Santarus” or the “Company”) (NASDAQ: SNTS) complied with their fiduciary duties in connection with the proposed buyout of the Company by Salix Pharmaceuticals, Ltd. Under the terms of the merger agreement, if the transaction closes Salix will acquire all the outstanding shares of SNTS for $32 per share. The firm’s investigation seeks to determine, among other things, whether the consideration to be paid to Santarus shareholders is fair and adequate. Current holders of Santarus common stock with questions concerning their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. or Marshall P. Dees, Esq. via email at email@example.com, or firstname.lastname@example.org, or via toll-free telephone at (888) 508-6832. Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.